Cipla Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Cipla şirketinin toplam hissedar öz sermayesi ₹284.6B ve toplam borcu ₹1.6B olup, bu da borç-öz sermaye oranını 0.6% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ₹346.6B ve ₹62.0B dir. Cipla 'in FAVÖK'ü ₹57.3B faiz karşılama oranı -36.5 dur. Şirketin ₹87.1B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

0.6%

Borç/özkaynak oranı

₹1.62b

Borç

Faiz karşılama oranı	-36.5x
Nakit	₹87.08b
Eşitlik	₹284.56b
Toplam yükümlülükler	₹62.00b
Toplam varlıklar	₹346.55b

Son finansal sağlık güncellemeleri

Recent updates

Cipla Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Nov 01

Cipla Limited's (NSE:CIPLA) Share Price Could Signal Some Risk

Sep 29

Cipla (NSE:CIPLA) Is Increasing Its Dividend To ₹13.00

Jun 06

Cipla's (NSE:CIPLA) Upcoming Dividend Will Be Larger Than Last Year's

May 21

Earnings Update: Cipla Limited (NSE:CIPLA) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

May 14

With EPS Growth And More, Cipla (NSE:CIPLA) Makes An Interesting Case

May 03

Is Cipla (NSE:CIPLA) Using Too Much Debt?

Feb 14

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Jan 26

Getting In Cheap On Cipla Limited (NSE:CIPLA) Is Unlikely

Jan 08

Is Cipla (NSE:CIPLA) Using Too Much Debt?

Nov 15

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Oct 05

Does Cipla (NSE:CIPLA) Have A Healthy Balance Sheet?

Aug 04

Is Cipla (NSE:CIPLA) A Risky Investment?

Mar 24

A Look At The Fair Value Of Cipla Limited (NSE:CIPLA)

Mar 06

Cipla (NSE:CIPLA) Has A Pretty Healthy Balance Sheet

Dec 11

Estimating The Fair Value Of Cipla Limited (NSE:CIPLA)

Aug 19

Cipla (NSE:CIPLA) Will Pay A Dividend Of ₹5.00

Jul 30

Cipla (NSE:CIPLA) Could Easily Take On More Debt

Jul 14

If EPS Growth Is Important To You, Cipla (NSE:CIPLA) Presents An Opportunity

Jul 01

Cipla Limited (NSE:CIPLA) Shares Could Be 34% Above Their Intrinsic Value Estimate

Apr 30

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Mar 23

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Dec 18

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CIPLA 'nin kısa vadeli varlıkları ( ₹209.5B ) kısa vadeli yükümlülüklerini ( ₹54.5B ) aşıyor.

Uzun Vadeli Yükümlülükler: CIPLA şirketinin kısa vadeli varlıkları ( ₹209.5B ) uzun vadeli yükümlülüklerini ( ₹7.4B ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CIPLA şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: CIPLA 'nin borç/öz sermaye oranı son 5 yılda 22.4% seviyesinden 0.6% seviyesine düştü.

Borç Kapsamı: CIPLA 'nin borcu işletme nakit akışı ( 2775% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: CIPLA ödediğinden daha fazla faiz kazandırıyor, dolayısıyla faiz ödemelerinin karşılanması bir sorun teşkil etmiyor.

Cipla Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Cipla (NSE:CIPLA) Using Too Much Debt?

Is Cipla (NSE:CIPLA) Using Too Much Debt?

Does Cipla (NSE:CIPLA) Have A Healthy Balance Sheet?

Is Cipla (NSE:CIPLA) A Risky Investment?

Cipla (NSE:CIPLA) Has A Pretty Healthy Balance Sheet

Cipla (NSE:CIPLA) Could Easily Take On More Debt

Recent updates

Cipla Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Second quarter 2025 earnings: EPS exceeds analyst expectations

Cipla, Alkem Laboratories Reportedly in Final Lap to Buy SMT

Cipla Limited Announces Executive Appointments

Cipla Limited to Report Q2, 2025 Results on Oct 29, 2024

Cipla Limited's (NSE:CIPLA) Share Price Could Signal Some Risk

Cipla Limited Announces Resignation of M K Hamied as Vice Chairman and Non-Executive Director, Effective October 29, 2024

Cipla Limited Announces Retirement of S. Radhakrishnan, Non-Executive Director

Cipla Limited to Report Q1, 2025 Results on Jul 26, 2024

Cipla (NSE:CIPLA) Is Increasing Its Dividend To ₹13.00

Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA

Cipla's (NSE:CIPLA) Upcoming Dividend Will Be Larger Than Last Year's

Cipla Limited Approves the Appointment of Dr. Balram Bhargava as an Independent Director

Promoter Group Entities Reportedly Likely to Sell 2.5% Stake in Cipla worth INR 26.37 Billion via Block Deals

Earnings Update: Cipla Limited (NSE:CIPLA) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Dividend increased to ₹13.00

Cipla Limited, Annual General Meeting, Aug 20, 2024

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Cipla Limited Announces Retirement of S. Radhakrishnan as Non-Executive Director

With EPS Growth And More, Cipla (NSE:CIPLA) Makes An Interesting Case

Cipla Limited to Report Q4, 2024 Results on May 10, 2024

Cipla Limited Appoints Rajeev Kumar Sinha as Senior Management Personnel and Global Chief Manufacturing Officer, Effective April 1, 2024

Cipla Limited Appoints Venkata Sai Mungara as Senior Management Personnel and Global Head - Supply Chain, Effective from 1 April 2024

Is Cipla (NSE:CIPLA) Using Too Much Debt?

Price target increased by 8.7% to ₹1,391

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Cipla Limited Announces Resignation of Ms. Samina Hamied as Executive Vice Chairperson

Third quarter 2024 earnings: EPS exceeds analyst expectations

Getting In Cheap On Cipla Limited (NSE:CIPLA) Is Unlikely

Is Cipla (NSE:CIPLA) Using Too Much Debt?

Second quarter 2024 earnings released: EPS: ₹14.01 (vs ₹9.78 in 2Q 2023)

Torrent Pharmaceuticals Reportedly Bid to Acquire the Stake of Cipla Stalled over Valuation Differences

Torrent Pharma Calls the Reports of Cipla Acquisition as Speculative

Family Rift Clouds $7 Billion Sale of Cipla

Cipla Limited to Report Q2, 2024 Results on Oct 27, 2023

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Blackstone Reportedly Withdraws Plan to Acquire Founders' Stake in Cipla

Torrent Pharma Reportedly in Advance Talks with CVC Capital to Buyout Cipla Promoters

Cipla's Founding Family's Stake Sale Reportedly in Jeopardy over $13 Billion Valuation Target

Bain Capital Reportedly Approaches Dr. Reddy's Laboratories to Explore Joint Bid to Buy Out the Promoters of Cipla

Torrent Pharmaceutical Leads in the Race to Acquire Cipla

Torrent Reportedly in Top Gear to Close Out Cipla Buyout, in Talks with PES, Banks for Funds

Torrent Reportedly Joins Fray for Hamied Family Stake in Cipla

Blackstone Reportedly to Submit Bid for over 33% Stake in Cipla

Does Cipla (NSE:CIPLA) Have A Healthy Balance Sheet?

Cipla Promoters Reportedly Mull Stake Sale to Top PE Firms Blackstone, Baring Asia

Cipla Limited Announces Change in Management

Full year 2023 earnings: EPS misses analyst expectations

Cipla Limited, Annual General Meeting, Aug 10, 2023

Cipla Limited to Report Q1, 2024 Results on Jul 26, 2023

Shibam Group Holding Limited entered into a binding term sheet to acquire additional 51% stake in Saba Investment Ltd from Cipla Limited (NSEI:CIPLA) for $6.5 million.

Full year 2023 earnings: EPS misses analyst expectations

Cipla Limited Announces Resignation of Peter Mugyenyi as Independent Director, Effective May 13, 2023

Is Cipla (NSE:CIPLA) A Risky Investment?

A Look At The Fair Value Of Cipla Limited (NSE:CIPLA)

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Cipla Limited Announces the Launch of Cippoint

Cipla Limited to Report Q3, 2023 Results on Jan 25, 2023

Cipla (NSE:CIPLA) Has A Pretty Healthy Balance Sheet

Cipla Limited and Cipla Usa Inc. Announces the Launch of Leuprolide Acetate Injection Depot 22.5Mg

Price target increased to ₹1,208

Price target increased to ₹1,202

Second quarter 2023 earnings: EPS exceeds analyst expectations

Cipla Limited to Report Q2, 2023 Results on Nov 04, 2022

Cipla Limited Receives the Establishment Inspection Report Indicating Closure of the Inspection

Cipla Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Cipla Limited (NSEI:CIPLA) agreed to acquire additional 13.10% stake in Jiangsu Acebright Pharmaceutical Co. Limited for USD 16.40 million.

Estimating The Fair Value Of Cipla Limited (NSE:CIPLA)

Cipla Limited Announces Executive Changes